Treatment with BIIB059, a monoclonal antibody targeting BDCA2, improves skin lesions in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE)

Background: Plasmacytoid dendritic cells (pDC) produce large amounts of type I IFN (IFN-I), cytokines convincingly linked to SLE and CLE pathogenesis. BIIB059 is a humanized mAb that binds BDCA2, a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. A first-in-human study was conducted to assess safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of single BIIB059 doses in healthy volunteers (HV) and patients with SLE with active CLE disease as well as proof of biological activity and clinical response in the SLE cohort (NCT02106897).

Source: Journal of the American Academy of Dermatology - August 21, 2019 Category: Dermatology Source Type: research